The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics (NASDAQ:CRSP) revealed 9 unusual trades. Delving into the details, ...

CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active ...